News & Updates

Upgrade Subscription

14 November 2024

Patent Updates

Ferric Citrate Comes Off Patent

Ferric citrate is indicated to control serum phosphorous in adults with chronic kidney disease who require dialysis.7 Tetraferric tricitrate decahydrate is also indicated to treat iron deficiency anemia in adults with chronic kidney disease who are not on dialysis. Ferric Citrate was developed by Panion & Bf Biotech ([Tw]).
The API has now reached off-patent status, after being launched in 1921.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Ferric Citrate was exported from India in 1921 , with an average price over the period of $26 /kg.
The key suppliers were West Bengal Chemical Industries, with a focus on markets in Asia Pacific.

For enquiries regarding more detailed trade data of Ferric Citrate and many others, contact info@pharmacheminvestor.com

Get started today.

PharmaChem Investor is your all-in-one solution for making strategic decisions, and driving innovation in the dynamic world of pharmaceuticals.

We notice you're using a small screen...

PharmaChem Investor is designed and optimised best for desktop devices and large screens, to make the most of all of the data available. We recommend accessing the site on a desktop device.

Logout